Free | Self-Paced | 0.75 hour COPE
Instructors:
Rishi P. Singh, MD, FASRS
Chair, Mass Eye and Ear, MGB
Peter A. Campochiaro, MD
Eccles Prof. Ophthalmology & Neuroscience
The Wilmer Institute, Johns Hopkins University SOM
Intravitreally administered anti-vascular endothelial growth factor (anti-VEGF) therapies have transformed the treatment landscape for neovascular age-related macular degeneration (nAMD), and diabetic macular edema (DME). However, clinicians need ongoing education on these emerging therapies and the real-world patient experiences with them.
An expert panel of two ophthalmologists will explore how anti-angiogenesis agents can help reduce treatment burden faced by patients while achieving optimal vision outcomes. This educational session will help clinicians understand the magnitude of the burden of retinal diseases and to emphasize the urgency of early diagnosis and evidence-based treatments to reduce frequent visits and improve patient outcomes.
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the New England College of Optometry (NECO).